ANGIOSARCOMA
Clinical trials for ANGIOSARCOMA explained in plain language.
Never miss a new study
Get alerted when new ANGIOSARCOMA trials appear
Sign up with your email to follow new studies for ANGIOSARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Sea Sponge-Inspired drug fights rare aggressive cancers
Disease control OngoingThis study is testing whether the drug eribulin can help control two rare types of blood vessel cancers: angiosarcoma and epithelioid hemangioendothelioma (EHE). The trial involves adults whose cancer has continued to grow despite previous treatments. Researchers want to see if t…
Matched conditions: ANGIOSARCOMA
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
Major trial aims to tame dozens of rare, neglected cancers with immune power combo
Disease control OngoingThis large national trial is testing whether a combination of two immunotherapy drugs (nivolumab and ipilimumab) can help control over 50 different types of rare cancers that have few or no standard treatment options. It enrolled over 800 adults whose rare cancers had progressed …
Matched conditions: ANGIOSARCOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
Personalized cancer vaccine trial halted before launch
Disease control TerminatedThis was an early, withdrawn study to test the safety of a personalized vaccine for a rare and aggressive skin cancer called angiosarcoma. The vaccine would have been made from a patient's own immune cells and tumor tissue. The main goal was to find a safe dose and see if the bod…
Matched conditions: ANGIOSARCOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC